Share on StockTwits

Valeant Pharmaceuticals Intl (NYSE:VRX) has received a consensus rating of “Buy” from the seventeen analysts that are presently covering the stock, American Banking and Market News reports. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $150.90.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 0.13% during mid-day trading on Tuesday, hitting $121.365. The stock had a trading volume of 306,777 shares. Valeant Pharmaceuticals Intl has a 52-week low of $83.45 and a 52-week high of $153.10. The stock has a 50-day moving average of $127.3 and a 200-day moving average of $129.. The company’s market cap is $40.690 billion. Valeant Pharmaceuticals Intl also was the recipient of some unusual options trading activity on Monday. Stock traders bought 8,293 call options on the stock. This is an increase of approximately 150% compared to the typical daily volume of 3,323 call options.

Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.04. The company had revenue of $1.85 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 76.6% on a year-over-year basis. Analysts expect that Valeant Pharmaceuticals Intl will post $8.73 EPS for the current fiscal year.

A number of research firms have recently commented on VRX. Analysts at Cantor Fitzgerald raised their price target on shares of Valeant Pharmaceuticals Intl to $209.00 in a research note on Monday, June 2nd. Separately, analysts at CIBC initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, May 21st. They set an “outperform” rating and a $160.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, May 16th. They now have a $153.00 price target on the stock.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.